BioLineRx Ltd.
For the period ended Aug 18, 2026. Filed Aug 18, 2026.
View on SEC.govAbout this filing
What a company based outside the US has published at home or sent to its shareholders. It is how many foreign companies share results and news between annual reports.
Aug 18, 2026 · Filed Aug 18, 2026
Use the contents to explore the available documents and sections.
Contents
EX-99.2 · PROXY STATEMENT
Proxy Statement for the Meeting) in Proposal 3, unless such shareholder has delivered a written notice to the Company notifying of the existence of a personal interest no later than 10:00 a.m. (Israel time) on Wednesday, September 23, 2026. Any such written notice must be sent to the Company via registered mail at the Company’s Offices; Attention: Chief Financial Officer. |
| (CONTINUED AND TO BE SIGNED ON REVERSE SIDE) | See Reverse Side |
|---|
ANNUAL GENERAL MEETING OF SHAREHOLDERS OF
BIOLINERX LTD.
September 23, 2026
| THIS PROXY, WHEN PROPERLY EXECUTED, WILL BE VOTED AS DIRECTED HEREIN. IF NO DIRECTION IS INDICATED, THIS PROXY WILL BE VOTED “FOR” THE ELECTION OF THE DIRECTORS NAMED IN ITEM 1 AND “FOR” ALL OTHER PROPOSALS. | ||||
|---|---|---|---|---|
| Please mark your vote for the following resolutions as in this example ☒ | ||||
| 1 | TO APPROVE the re-election of the following persons as Class III directors, each to serve until the Company’s annual general meeting of shareholders to be held in 2029, and until their respective successors have been duly elected and qualified. | FOR | AGAINST | ABSTAIN |
| Dr. Aharon Schwartz | ☐ | ☐ | ☐ | |
| Dr. Sandra Panem | ☐ | ☐ | ☐ | |
| Dr. Shaoyu Yan | ☐ | ☐ | ☐ | |
| 2. | TO APPROVE an increase in the Company’s authorized share capital, and to amend the Company’s Articles of Association accordingly. | FOR ☐ | AGAINST ☐ | ABSTAIN ☐ |
| 3. | TO APPROVE the grant of equity-based compensation, in the form of options and performance stock units, to Philip Serlin, the Company’s Chief Executive Officer. | FOR ☐ | AGAINST ☐ | ABSTAIN ☐ |
| 4. | TO APPROVE the grant of equity-based compensation in the form of options to certain directors of the Company. | FOR ☐ | AGAINST ☐ | ABSTAIN ☐ |
| 5. | TO APPROVE the reappointment of Kesselman & Kesselman, Certified Public Accountants (Isr.), a member firm of PricewaterhouseCoopers International Limited, as the Company’s independent registered public accounting firm for the year ending December 31, 2026, and until the Company’s next annual general meeting of shareholders, and to authorize the
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.